• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·STSN
Share

Stemsation International, Inc. Stocks

$ 0.02Last Updated 19.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 9.48M

$ 0.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

StemSation International, Inc., headquartered in Boca Raton, Florida, specializes in the development, manufacture, and distribution of natural wellness products. These offerings are specifically designed to bolster the human body's stem cell and endocannabinoid systems. Among its key products is StemRCM, a nutritional supplement created to enhance stem cells' natural capacity to mend, rejuvenate, and revitalize bodily tissues and organs. This is achieved by promoting healthy stem cell liberation, transport, and targeting within the system. The company markets its goods directly to consumers through a network of independent health advocates.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 11:49

Meta is ramping up its investment in AI: increasing spending and preparing to issue a new class of shares

22.10.2026 11:15

Tesla has scaled back its capital expenditure plans for 2026. Why investors weren't pleased

22.10.2026 10:48

Top Stories This Morning: Meta Has Increased Its AI Spending; Anthropic Has Unveiled a Competitor to Muse

22.10.2026 10:33

Millions of Hacking Attempts: 5 Questions About a Critical Network Vulnerability Discovered by AI

21.10.2026 22:53

"Ambitions Greater Than Anyone Else's": JPMorgan Expects SpaceX Shares to Triple in Value

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026